Could the extension of Cigna (CI) AI imaging reflect a deeper bet on integrated healthcare innovation?

• Cleerly announced in late September 2025 that Cigna will begin covering Cleerly Labs Advanced Plaque Analysis with over 16 million members starting October 1, 2025, and will join major insurers such as UnitedHealthcare and Evicore to expand access to AI-powered coronary imaging for cardiovascular care.
• The move marks a rapid industry shift to more than 61 million Americans with coverage of AI-QCT and coronary plaque analysis technology, increasing diagnostic accuracy and adopting artificial intelligence for more informational healthcare decisions.
• Cigna explores how AI-powered cardiovascular imaging embraces affect the investment narrative focused on innovation and integrated care.

Today's best AI stock may surpass giants like Nvidia and Microsoft. Discover the next great opportunity with these 24 small AI-focused companies through early stage innovations in machine learning, automation, and data intelligence that can fund your retirement.

Cigna Group Investment story summary

To become a shareholder of Cigna, you need to believe in your ability to maintain profitable growth by navigating industry disruptions while capturing the demand for integrated care and professional services. Recent moves covering AI-powered plaque analysis reinforce Cigna's innovation narrative, but virtually does not change the short-term catalyst. This will continue to change ongoing revenue growth through the Margin Evernorth business and not change the key risks regarding potential regulatory changes in PBM operations.

In a recent announcement, Cigna's significant share buyback stands out as the most relevant, reflecting management's confidence in future revenues that are closely tied to drivers and risks highlighted by the AI ​​imaging coverage decision. These actions provide support for growth per share, but do not rule out the uncertainty of ongoing regulations regarding pharmacy profit management reforms.

However, investors should note that disruptive regulations affecting PBM margins are still risky…

Read the complete story of the Cigna group (free!)

The Cigna Group's story project will project revenue of $299.7 billion and revenue of $7.8 billion by 2028. This requires an annual revenue growth of 4.6% and an increase of $2.8 billion in revenues from today's $5 billion.

It reveals how Cigna Group's forecasts will provide a fair value of $369.13.

Explore other perspectives

The 10 fair value estimates from the Simply Wall St community range from USD 275 to USD 1,162, reflecting a significant difference in the expected rise. With Cigna's ongoing regulatory scrutiny of PBM leadership, it's now a good time to compare your views with others and explore the full discussion.

Explore 10 other fair value estimates at Cigna Group – why inventory is worth more than three times more than current prices!

Build your own Signa Group stories

Do you oppose existing stories? Create your own creation within 3 minutes – extraordinary investment returns rarely come from following the flock.

Looking for alternative opportunities?

The market won't wait. These fast stocks are hot now. Grab the list before they run:

This article simply by Wall Street is inherently common. We provide commentary based on historical data and analyst forecasts, and use impartial methodologies, and our articles are not intended for financial advice. It is not a recommendation to buy or sell stocks and does not take into account your goals or financial situation. We aim to deliver long-term intensive analysis driven by basic data. Please note that the analysis may not take into account the latest price-sensitive company announcements and qualitative material. Simply put, the Wall ST has no position in the stock mentioned.

Do you have feedback in this article? Are you worried about the content? Please contact us directly. Alternatively, please email editorial-team@simplywallst.com